SOUTH SAN FRANCISCO, Calif. October 18, 2016 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ® (atezolizumab) for the treatment of people with ... PharmaVOICE, 23 hours ago
Genentech???s Tecentriq Wins Second Approval of the Year, This Time for Lung Cancer - BioSpace, 1 day ago
FDA Approves Genentech 's Cancer Immunotherapy TECENTRIQ ® (Atezolizumab) for People with a Specific Type of Metastatic Lung Cancer - Stockwatch, 2 days ago
2 images for "genentech rank"
- Group sales increase 4%1 at constant exchange rates, 6% in Swiss francs - Pharmaceuticals Division sales up 4%, driven by oncology and immunology medicines - Diagnostics Division sales grow 7%, primarily due to immunodiagnostic products - ...Pharmacy Choice, 4 hours ago
By Alex Keown , BioSpace.com Breaking News Staff For a newly mortar-boarded PhD in the life sciences or a seasoned veteran of the pharma and biotech world, when searching for a new job, it's a pretty basic notion to look for work where the jobs ...BioSpace, 9 hours ago Top 5 Best U.S. Cities for Life Science Research Associate Jobs BioSpace, 2 weeks ago These Biotech Employers Hired the Most New Grads In Life Sciences BioSpace, 1 month ago Best Places to Work in Life Sciences for LGBT Equality BioSpace, 1 month ago
FirstWord NPS+ Rheumatoid Arthritis (US) Introduction Satisfaction survey results: Top 2 brands are way ahead of the pack. Can your brand close the gap? In the US rheumatoid arthritis (RA) treatment market, the two leading brands are ...MarketResearch.com, 12 hours ago
Chugais Alecensa Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer
-- Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the first-line treatment of ALK positive non-small cell lung cancer (NSCLC) to Alecensa ® , ...PressReleasePoint, 2 days ago Chugai's Alecensa® Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer Nasdaq, 2 weeks ago CHUGAI PHARMACEUTICAL : Alecensa Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer 4 Traders, 2 weeks ago Chugai Pharma's Alecensa Receives Breakthrough Therapy Designation From FDA For First-Line Treatment Of ALK Positive Non-Small Cell Lung Cancer BioSpace, 2 weeks ago
Identify the Atrophy of Alzheimer's Disease, Mild Cognitive Impairment and Normal Aging Using Morphometric MRI Analysis
Introduction Alzheimer's disease (AD) is an insidious onset neurodegenerative disease primarily characterized by progressive memory loss and accompanied by several kinds of cognitive and functional impairment ( McKhann et al., 2011 ). Medial ...Frontiers in Neurorobotics, 2 days ago
Expressing concern over the growing threat posed by counterfeit drugs in India and abroad, the Pharmaceutical Security Institute (PSI), a not-for-profit corporation based in Washington engaged in protecting patient safety, sharing information on the ...PharmaBiz, 2 days ago
innovatED to Feature Earthquake Emergency Response Simulations and State-of-the-Art Technology Las Vegas — Demonstrations by nearly 50 companies of cutting-edge technologies and devices are being featured this week in Las Vegas during the ...American College of Emergency Physicians, 4 days ago
Amgen has focused the company's business and operating model through significant transformation and process improvement efforts to produce significant, innovative medicines while generating satisfactory investor returns. Amgen Inc. ...Pharma Live, 6 days ago
Wall Street stocks look set to start Tuesday 's session on a negative note, as oil fell on doubts about a possible of OPEC production deal. The Redbook index and Labor Market Conditions Index to be released today will be reflected on the market.RTTNews.com, 1 week ago
on your WebpageAdd Widget >Get your members hooked!